Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

06.10.2025

1 Acta Haematol
3 Am J Hematol
4 Ann Hematol
4 Blood
1 BMC Cancer
1 Br J Cancer
1 Cancer Chemother Pharmacol
3 Cancer Lett
1 Cancer Res
2 Int J Hematol
2 Leuk Res
8 Leukemia
1 Oncol Rep
2 Proc Natl Acad Sci U S A


    Acta Haematol

  1. MIN KI, Kwag D, Min GJ, Park SS, et al
    Ponatinib Monotherapy in adult patients with Relapsed or Refractory Philadelphia-Positive Acute Lymphoblastic Leukemia: A Real-World Retrospective Analysis Including MRD Relapse.
    Acta Haematol. 2025 Oct 2:1-22. doi: 10.1159/000548544.
    >> Share


    Am J Hematol

  2. SOCKEL K, Rollig C, Mutherig A, Crysandt M, et al
    Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.
    Am J Hematol. 2025 Oct 2. doi: 10.1002/ajh.70091.
    >> Share

  3. VALTIS YK, Nemirovsky D, Derkach A, Cacace I, et al
    Venetoclax in Combination With Pediatric-Inspired Chemotherapy in Adults With Newly Diagnosed Acute Lymphoblastic Leukemia: Results of a Phase I Trial.
    Am J Hematol. 2025 Sep 27. doi: 10.1002/ajh.70082.
    >> Share

  4. FATHIMA S, Alsugair A, Yousuf M, Faldu P, et al
    Validation of BLAST and BLAST-Mol Risk Models in Chronic Myelomonocytic Leukemia: Mayo-Humanitas Collaborative Project Involving 1101 Patients.
    Am J Hematol. 2025 Sep 25. doi: 10.1002/ajh.70080.
    >> Share


    Ann Hematol

  5. YANG Y, Zhang X, Jiang N, Jin Y, et al
    Correction to: Prognostic value of dynamic minimal residual disease monitoring for adolescent and adult T-lymphoblastic leukemia/lymphoma.
    Ann Hematol. 2025 Oct 1. doi: 10.1007/s00277-025-06665.
    >> Share

  6. DAI Y, Ai Y, Sun S, Tang M, et al
    Treatment of EPOR-rearranged acute lymphoblastic leukemia with ruxolitinib: case reports and review of the literature.
    Ann Hematol. 2025 Sep 29. doi: 10.1007/s00277-025-06596.
    >> Share

  7. LI ST, Shi XM, Liu QJ, Tan YH, et al
    Internal tandem duplications of FLT3 containing exogenous sequences are associated with poor clinical outcomes in acute myeloid leukemia.
    Ann Hematol. 2025 Sep 26. doi: 10.1007/s00277-025-06618.
    >> Share

  8. CHEN H, Chen M, Yang Z, Liao S, et al
    Identification of a novel PML exon 6 splice variant in atypical PML::RARalpha transcripts in acute promyelocytic leukemia.
    Ann Hematol. 2025 Sep 26. doi: 10.1007/s00277-025-06613.
    >> Share


    Blood

  9. PENTER L, Maurer K, Cieri N, Lu W, et al
    Mechanisms of immune escape and extramedullary tropism in leukemia cutis.
    Blood. 2025 Sep 30:blood.2025029121. doi: 10.1182/blood.2025029121.
    >> Share

  10. DEREVYANKO PK, Swart LE, Mata Casimiro LD, van Oort A, et al
    Fusion Gene Depletion Eliminates Stemness and Induces Bidirectional Differentiation of Acute Myeloid Leukemia.
    Blood. 2025 Sep 24:blood.2025028988. doi: 10.1182/blood.2025028988.
    >> Share

  11. NEDUMANNIL R, Ashby M, Rowland J, Malherbe JAJ, et al
    Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.
    Blood. 2025;146:1625-1629.
    >> Share

  12. RODDIE C, Dias J, O'Reilly MA, Abbasian M, et al
    Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion.
    Blood. 2025;146:1664-1676.
    >> Share


    BMC Cancer

  13. XIONG Y, Chen Y, Luo H, Shi M, et al
    DHX9 as a prognostic biomarker and its biological roles in acute myeloid leukemia.
    BMC Cancer. 2025;25:1464.
    >> Share


    Br J Cancer

  14. GIL JV, Avetisyan G, Miralles A, de Las Heras S, et al
    Benchmarking standard-of-care and emerging genomic approaches to enhance diagnosis in pediatric acute lymphoblastic leukemia.
    Br J Cancer. 2025 Sep 30. doi: 10.1038/s41416-025-03204.
    >> Share


    Cancer Chemother Pharmacol

  15. COHEN IJ
    Comment on: Dose adjustment strategy for high dose methotrexate-induced toxicities in pediatric acute lymphoblastic leukemia: based on population PK analysis and exposure toxicity relationship.
    Cancer Chemother Pharmacol. 2025;95:95.
    >> Share


    Cancer Lett

  16. MA W, Jamieson C
    Developmental checkpoint targeting: Pre-TCR immunotherapy in leukemia and beyond.
    Cancer Lett. 2025 Sep 26:218063. doi: 10.1016/j.canlet.2025.218063.
    >> Share

  17. MILLS TS, Arnone M, Gorsch E, Poeschel S, et al
    MRC2 expression modulates metabolism in acute myeloid leukemia stem cells.
    Cancer Lett. 2025 Sep 26:218068. doi: 10.1016/j.canlet.2025.218068.
    >> Share

  18. HE SJ, Shu LP, Zhou ZW, Yang T, et al
    Corrigendum to "Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells" [Cancer. Lett. (382) 2016-11-28; 382(2):215-230].
    Cancer Lett. 2025 Sep 27:218039. doi: 10.1016/j.canlet.2025.218039.
    >> Share


    Cancer Res

  19. ZWICK M, Zinkel B, Spohr C, Ruckert T, et al
    FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia.
    Cancer Res. 2025 Oct 3. doi: 10.1158/0008-5472.CAN-25-0349.
    >> Share


    Int J Hematol

  20. AKAHANE K, Kasai S, Tamai M, Sugita Y, et al
    Utility of tolvaptan sodium phosphate for refractory fluid retention in post-transplant sinusoidal obstruction syndrome.
    Int J Hematol. 2025;122:611-615.
    >> Share

  21. IMI T, Asakura H, Sato K, Yamada S, et al
    Transient lupus anticoagulant induced by adenovirus cystitis in a bone marrow transplant recipient.
    Int J Hematol. 2025 Jun 5. doi: 10.1007/s12185-025-04020.
    >> Share


    Leuk Res

  22. SHANG J, Chen WM, Liu S, Wang ZH, et al
    Corrigendum to "CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy" [Leuk. Res., 85 (2019) 106198].
    Leuk Res. 2025 Sep 23:108111. doi: 10.1016/j.leukres.2025.108111.
    >> Share

  23. FUJIOKA M, Mishima H, Itonaga H, Hamaguchi Y, et al
    Genes with altered expression by 5-Aza treatment in myeloid leukemia cells through methylation in intron 1.
    Leuk Res. 2025;158:108112.
    >> Share


    Leukemia

  24. SMITH C, Charbonnier G, Simonin M, Balducci E, et al
    Towards methylation-based redefinition of TAL1 positive T-cell acute lymphoblastic leukaemia (T-ALL).
    Leukemia. 2025;39:2344-2354.
    >> Share

  25. KAPAHNKE K, Plenge T, Klaus T, Gupta MK, et al
    The histone-methyltransferase DOT1L cooperates with LSD1 to control cell division in blast-phase MPN.
    Leukemia. 2025;39:2406-2418.
    >> Share

  26. PEREZ-AMILL L, Armand-Ugon M, Val-Casals M, Martin-Herreros B, et al
    A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias.
    Leukemia. 2025;39:2432-2441.
    >> Share

  27. MOINARD S, Lebecque B, Lachaise T, Johnson-Ansah H, et al
    Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools.
    Leukemia. 2025;39:2375-2383.
    >> Share

  28. TIRTAKUSUMA R, Ghonim MA, Schattgen S, Muller B, et al
    Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias.
    Leukemia. 2025;39:2419-2431.
    >> Share

  29. ZHANG X, Li M, Chen Y, Liu J, et al
    Deubiquitinase USP6 stabilizes oncogenic RUNX1 fusion proteins to promote the leukemic potential and malignant progression.
    Leukemia. 2025;39:2355-2363.
    >> Share

  30. SETIAWAN T, Muhammad JA, Marcellina N, Wirawan LM, et al
    Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis.
    Leukemia. 2025 Oct 1. doi: 10.1038/s41375-025-02768.
    >> Share

  31. TEDESCHI A, Frustaci AM, Menna P, Minotti G, et al
    Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
    Leukemia. 2025 Oct 2. doi: 10.1038/s41375-025-02778.
    >> Share


    Oncol Rep

  32. ZHOU X, Li A, Kong D, Shi Y, et al
    The silent players: Atypical BCR?ABL isoforms as biomarkers and therapeutic hurdles in CML pathogenesis (Review).
    Oncol Rep. 2025;54:162.
    >> Share


    Proc Natl Acad Sci U S A

  33. TAN M, Sun S, Liu Y, Perreault AA, et al
    Targeting the 3D genome by anthracyclines for chemotherapeutic effects.
    Proc Natl Acad Sci U S A. 2025;122:e2500704122.
    >> Share

  34. HATTORI T, Wang M, Corrado AD, Gross S, et al
    Engineering antibody-drug conjugates targeting an adhesion GPCR, CD97.
    Proc Natl Acad Sci U S A. 2025;122:e2516627122.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016